Lyka Labs Limited has announced the grant of an Indian patent for its innovative topical product, Pregabalin Gel 8%, with protection extending until 2043. This milestone underscores Lyka Labs’ commitment to advancing topical drug delivery systems and pharmaceutical innovation.
Pregabalin Gel 8% is a breakthrough formulation for the localized treatment of diabetic neuropathic pain, offering targeted relief with minimal systemic side effects compared to traditional oral medications. Approved by the Central Drugs Standard Control Organization (CDSCO) in October 2024, the product was officially launched in December 2024 by Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare under a P2P licensing agreement.
As the first-of-its-kind topical pregabalin formulation in India, this gel represents a major step forward in pain management. Lyka Labs’ clinical studies demonstrate the gel’s efficacy, safety, and ease of use, making it a promising solution for millions of patients suffering from chronic diabetic neuropathic pain.
The patent not only enhances Lyka Labs’ intellectual property portfolio but also reinforces its mission to provide innovative pharmaceutical solutions. With a strong focus on patient-centric therapies, Lyka continues to lead in developing effective and safe alternatives for chronic conditions.
